ATE404668T1 - Wachstumsfaktor-homologe zvegf-3 - Google Patents

Wachstumsfaktor-homologe zvegf-3

Info

Publication number
ATE404668T1
ATE404668T1 AT99966032T AT99966032T ATE404668T1 AT E404668 T1 ATE404668 T1 AT E404668T1 AT 99966032 T AT99966032 T AT 99966032T AT 99966032 T AT99966032 T AT 99966032T AT E404668 T1 ATE404668 T1 AT E404668T1
Authority
AT
Austria
Prior art keywords
zvegf
growth factor
polypeptides
seq
residues
Prior art date
Application number
AT99966032T
Other languages
English (en)
Inventor
Zeren Gao
Charles Hart
Christopher Piddington
Paul Sheppard
Kimberly Shoemaker
Debra Gilbertson
James West
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Application granted granted Critical
Publication of ATE404668T1 publication Critical patent/ATE404668T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
AT99966032T 1998-12-07 1999-12-07 Wachstumsfaktor-homologe zvegf-3 ATE404668T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US20712098A 1998-12-07 1998-12-07
US14257699P 1999-07-06 1999-07-06
US16165399P 1999-10-21 1999-10-21
US16525599P 1999-11-12 1999-11-12

Publications (1)

Publication Number Publication Date
ATE404668T1 true ATE404668T1 (de) 2008-08-15

Family

ID=27495530

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99966032T ATE404668T1 (de) 1998-12-07 1999-12-07 Wachstumsfaktor-homologe zvegf-3

Country Status (9)

Country Link
EP (2) EP1988102B1 (de)
JP (2) JP4739526B2 (de)
AT (1) ATE404668T1 (de)
AU (1) AU764039B2 (de)
CA (1) CA2354325C (de)
DE (1) DE69939330D1 (de)
DK (1) DK1137773T3 (de)
ES (2) ES2432053T3 (de)
WO (1) WO2000034474A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000053758A2 (en) * 1999-03-08 2000-09-14 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US6455283B1 (en) 1998-03-17 2002-09-24 Genentech, Inc. Nucleic acids encoding vascular endothelial cell growth factor-E (VEGF-E)
DE69941791D1 (de) * 1998-11-10 2010-01-21 Ludwig Inst Cancer Res Von blutplättchen abstammender wachstumsfaktor d, dafür kodierende dns und deren verwendungen
US7148037B2 (en) 1998-11-10 2006-12-12 Ludwig Institute For Cancer Research Platelet-derived growth factor D, DNA coding therefor, and uses thereof
US7105481B2 (en) 1998-11-10 2006-09-12 Ludwig Institute For Cancer Research Method for stimulating connective tissue growth or wound healing
AU3737500A (en) * 1999-03-12 2000-09-28 Genentech Inc. Method of preventing the death of retinal neurons and treating ocular diseases
AU4008500A (en) * 1999-04-06 2000-10-23 Eli Lilly And Company Platelet-derived growth factor related gene and protein
US6630142B2 (en) 1999-05-03 2003-10-07 Zymogenetics, Inc. Method of treating fibroproliferative disorders
US6468543B1 (en) 1999-05-03 2002-10-22 Zymogenetics, Inc. Methods for promoting growth of bone using ZVEGF4
MXPA01011158A (es) * 1999-05-03 2004-06-03 Zymogenetics Inc Factor de crecimiento homologo zvegf4.
EP1222279A2 (de) * 1999-10-07 2002-07-17 Curagen Corporation Wachstumsfaktorenpolypeptide und nukleinsäuren die dafür kodieren
WO2001028586A1 (en) * 1999-10-21 2001-04-26 Zymogenetics, Inc. Method of treating fibrosis
US6893637B1 (en) 1999-10-21 2005-05-17 Zymogenetics, Inc. Method of treating fibrosis
AU2000251259A1 (en) * 2000-02-04 2001-08-14 Zymogenetics Inc. Methods for promoting growth of bone, ligament, and cartilage using zvegf4
US20040086507A1 (en) * 2000-10-19 2004-05-06 Kenya Shitara Antibody inhibiting vplf activity
NZ527975A (en) * 2001-03-09 2005-02-25 Janssen Pharmaceutica Nv Modulation of smooth muscle cell proliferation
WO2003065043A2 (en) * 2002-01-29 2003-08-07 King's College London An Institute Incorporated By Royal Charter Of Strand Identification and relative quantification of proteins
WO2004006898A2 (en) * 2002-07-11 2004-01-22 Sema Aps Use of compounds capable of inhibiting the proteolytic processing of semaphorins for prevention, treatment, diagnosis and prognosis of an invasive disease
WO2005011742A1 (en) * 2003-07-25 2005-02-10 Zymogenetics, Inc. Method of treating hepatocellular carcinoma
US8629836B2 (en) 2004-04-30 2014-01-14 Hillcrest Laboratories, Inc. 3D pointing devices with orientation compensation and improved usability
WO2005109879A2 (en) 2004-04-30 2005-11-17 Hillcrest Laboratories, Inc. Free space pointing devices and method
US8137195B2 (en) 2004-11-23 2012-03-20 Hillcrest Laboratories, Inc. Semantic gaming and application transformation
RU2014140116A (ru) 2012-04-24 2016-06-10 Тромбодженикс Н.В. Антитела против pdgf-c

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU560472B2 (en) 1981-08-25 1987-04-09 Celltech Limited Yeast expression vectors
US4579821A (en) 1981-11-23 1986-04-01 University Patents, Inc. Control of DNA sequence transcription
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US4486533A (en) 1982-09-02 1984-12-04 St. Louis University Filamentous fungi functional replicating extrachromosomal element
US4599311A (en) 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
US4977092A (en) 1985-06-26 1990-12-11 Amgen Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US5139936A (en) 1983-02-28 1992-08-18 Collaborative Research, Inc. Use of the GAL1 yeast promoter
US4661454A (en) 1983-02-28 1987-04-28 Collaborative Research, Inc. GAL1 yeast promoter linked to non galactokinase gene
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
US4766073A (en) 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
CA1280080C (en) 1984-12-06 1991-02-12 Jacques Oberto Promoters for the expression of foreign genes in yeast, plasmids comprising them, and uses thereof for the production of polypeptides
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US4882279A (en) 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
US4935349A (en) 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5124316A (en) 1986-11-14 1992-06-23 President And Fellows Of Harvard College Method for periodontal regeneration
US5219759A (en) 1987-04-22 1993-06-15 Chiron Corporation Recombinant DNA encoding PDGF A-chain polypeptide and expression vectors
US4980289A (en) 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
US5063154A (en) 1987-06-24 1991-11-05 Whitehead Institute For Biomedical Research Pheromone - inducible yeast promoter
US5094941A (en) 1987-12-31 1992-03-10 Zymogenetics, Inc. Monoclonal antibodies to PDGF
US5750375A (en) 1988-01-22 1998-05-12 Zymogenetics, Inc. Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
EP1762623A1 (de) 1988-01-22 2007-03-14 ZymoGenetics, Inc. Verfahren zur Produktion von biologisch aktiven Peptiddimeren
US4899919A (en) 1988-04-01 1990-02-13 Clumb Thomas E Self energizing fastener system
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5162228A (en) 1988-12-28 1992-11-10 Takeda Chemical Industries, Ltd. Gylceraldehyde-3-phosphate dehydrogenase gene and promoter
CA2006880A1 (en) 1989-01-03 1990-07-03 William D. Huse Push column and chromatography method
US5124263A (en) 1989-01-12 1992-06-23 Wisconsin Alumni Research Foundation Recombination resistant retroviral helper cell and products produced thereby
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5162222A (en) 1989-07-07 1992-11-10 Guarino Linda A Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses
US5219739A (en) 1989-07-27 1993-06-15 Scios Nova Inc. DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
US5234908A (en) 1991-04-12 1993-08-10 Creative Biomolecules, Inc. Method of treating gastrointestinal ulcers with platelet derived growth factor
US5298418A (en) 1991-09-16 1994-03-29 Boyce Thompson Institute For Plant Research, Inc. Cell line isolated from larval midgut tissue of Trichoplusia ni
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
WO1994006463A1 (en) 1992-09-14 1994-03-31 Pfizer Inc Immortalized cells and uses therefor
US5620687A (en) 1993-02-25 1997-04-15 Zymogenetics, Inc. Inhibition of intimal hyperplasia using antibodies to PDGF beta receptors
WO1995007358A1 (en) 1993-07-30 1995-03-16 University Of Medicine & Dentistry Of New Jersey Efficient gene transfer into primary lymphocytes
KR100289201B1 (ko) 1994-02-14 2001-05-02 엘. 데이예를 카렌. 조혈 단백질과 그것의 제조를 위한 재료 및 방법
CA2184584C (en) 1994-03-08 2003-04-08 Jing-Shan Hu Vascular endothelial growth factor 2
US5641655A (en) 1994-11-30 1997-06-24 Zymogenetics, Inc. Methods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptide
ATE252600T1 (de) 1995-03-02 2003-11-15 Amrad Operations Pty Ltd Ein neuartiger wachstumfaktor und eine genetische sequenz die für diesen kodiert
EP0853668B2 (de) 1995-09-29 2013-03-06 Vegenics Pty Ltd Regulierte gene und ihre verwendungen
US5955349A (en) 1996-08-26 1999-09-21 Zymogenetics, Inc. Compositions and methods for producing heterologous polypeptides in Pichia methanolica
US5716808A (en) 1995-11-09 1998-02-10 Zymogenetics, Inc. Genetic engineering of pichia methanolica
AU4977496A (en) 1996-02-12 1997-08-28 Human Genome Sciences, Inc. Human neuronal attachment factor-1
US5736383A (en) 1996-08-26 1998-04-07 Zymogenetics, Inc. Preparation of Pichia methanolica auxotrophic mutants
CN1230997A (zh) 1996-07-17 1999-10-06 津莫吉尼蒂克斯公司 甲醇毕赤酵母的转化
ES2327440T3 (es) * 1996-08-23 2009-10-29 Vegenics Limited Factor recombinante de crecimiento de las celulas endoteliales vasculares-d (vegf-d).
WO1998024811A2 (en) * 1996-12-06 1998-06-11 Zymogenetics, Inc. Vascular endothelial growth factor
US6455283B1 (en) * 1998-03-17 2002-09-24 Genentech, Inc. Nucleic acids encoding vascular endothelial cell growth factor-E (VEGF-E)
AU2562199A (en) * 1998-01-27 1999-08-09 Eli Lilly And Company Vegf related gene and protein
EP0984063A3 (de) * 1998-08-31 2000-08-16 Eli Lilly And Company Vegf-verwandtes gen und protein
CA2344561A1 (en) * 1998-09-30 2000-04-06 Ludwig Institute For Cancer Research Platelet-derived growth factor c, dna coding therefor, and uses thereof
EP1127122A2 (de) * 1998-10-28 2001-08-29 Incyte Pharmaceuticals, Inc. Wachstumsfaktor verwandte moleküle

Also Published As

Publication number Publication date
AU2167900A (en) 2000-06-26
EP1988102B1 (de) 2013-08-21
AU764039B2 (en) 2003-08-07
JP2002531127A (ja) 2002-09-24
EP1137773B1 (de) 2008-08-13
JP4739526B2 (ja) 2011-08-03
EP1137773A2 (de) 2001-10-04
EP1988102A1 (de) 2008-11-05
DE69939330D1 (de) 2008-09-25
DK1137773T3 (da) 2008-12-08
JP5345997B2 (ja) 2013-11-20
JP2011052009A (ja) 2011-03-17
WO2000034474A9 (en) 2002-08-29
CA2354325A1 (en) 2000-06-15
CA2354325C (en) 2011-08-16
WO2000034474A3 (en) 2000-12-28
ES2432053T3 (es) 2013-11-29
ES2312223T3 (es) 2009-02-16
WO2000034474A2 (en) 2000-06-15

Similar Documents

Publication Publication Date Title
ATE404668T1 (de) Wachstumsfaktor-homologe zvegf-3
DK0643767T3 (da) Osteogene peptider
HUP0101136A2 (hu) Fehérjeexpresszió baculovírus-vektort alkalmazó expressziós rendszerben
ATE80660T1 (de) Verfahren zur herstellung eines polypeptides.
DE68929043D1 (de) Für androgen-rezeptor-protein kodierende dna
CA2359242A1 (en) Growth differentiation factor inhibitors and uses therefor
ATE272109T1 (de) Rekombinante collagenase typ i aus clostridium histolyticum und ihre verwendung zur isolierung von zellen und zellverbänden
ATE417057T1 (de) Mutierte formen des fas liganden und deren verwendung
ATE121776T1 (de) Expression des biologisch aktiven faktors xiii.
DK175843B1 (da) Polypeptider af overfladeaktive alvelolarproteiner (ASP), farmaceutisk sammensætning indeholdende polypeptidet, DNA-ekspressionssystem der koder for polypeptidet, samt fremgangsmåde til fremstilling af polypeptider med ASP-aktivitet
CO4790156A1 (es) Polipeptidos de membrana de linfocito de mamifero y acidos nucleicos que los codifican
MXPA01011158A (es) Factor de crecimiento homologo zvegf4.
DE69233245D1 (de) Verfahren zur Herstellung von Peptiden
FI915654A0 (fi) Somatotropiner med alterneringar i alfahelixregionen 1 och kombinationer med andra mutationer.
DE69529750D1 (de) Verbesserungen in der herstellung von proteinen in wirtszellen
DE59712771D1 (de) Nebenhoden-spezifisches Rezeptorprotein und dessen Verwendung
ATE356205T1 (de) Milcherzeugungsassoziiertes immunotropisches rinderprotein (cd14), kodierendes gen und verwendung zur aktivierung von b-zellen
ATE123056T1 (de) Ancrod-proteine, ihre herstellung und verwendung.
ATE409746T1 (de) Neuer spannungsabhängiger kaliumkanal und seine verwendung zur entwicklung von therapeutika
WO2002012334A3 (en) Snake venom polypeptide zsnk1
ATE130872T1 (de) Ancrod ähnliche proteine, ihre herstellung und verwendung.
TH11411EX (th) อีพิธีลินส์
SG165136A1 (en) Recombinant molecules and uses therefor

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1137773

Country of ref document: EP